![]() |
|
|
Vol. 26, Issue 6, 520-527, June 1998
Department of Drug Metabolism, Merck Research Laboratories
The barriers to oral delivery of the hydrophilic zwitterion
L-767,679 (I) and its carboxyl ester prodrug L-775,318 (II) were examined. In the Caco-2 cell model, transport of II, but not I, was
strongly oriented in the secretory direction. The basal-to-apical transport of II displayed saturable kinetics and was markedly inhibited
by verapamil and quinidine, known P-glycoprotein inhibitors. In Caco-2
cells, metabolism of I was not observed, whereas hydrolysis of II was
modest (
20%). In the in situ rat intestinal loop model, verapamil did not affect the absorption of I but significantly increased the absorption of II. I was resistant to intestinal metabolism, whereas II underwent hydrolysis partially in rat lumen but
more extensively in rat intestinal tissue and blood. In
vitro metabolism studies indicated that verapamil also inhibited
the hydrolysis of II in rats. The inhibition was relatively specific for the intestinal and not the luminal esterases. These results suggested that the intestinal absorption of I was limited not by
intestinal efflux or metabolism but more likely by the low lipophilicity of I. However, an efflux system, likely mediated by
P-glycoprotein, played an important role in limiting the absorption of
II. In rats, metabolism served as an additional barrier to the
absorption of II. Verapamil increased the intestinal absorption of the
prodrug by inhibiting the efflux system in the two models studied, as
well as possibly inhibiting metabolism in rats. For the first time,
secretory transport was identified as a cause of the failure to
increase the absorption of a lipophilic and cationic prodrug developed
to overcome the absorption problem.
This article has been cited by other articles:
![]() |
K. Masaki, M. Hashimoto, and T. Imai Intestinal First-Pass Metabolism via Carboxylesterase in Rat Jejunum and Ileum Drug Metab. Dispos., July 1, 2007; 35(7): 1089 - 1095. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Masaki, M. Taketani, and T. Imai FIRST-PASS HYDROLYSIS OF A PROPRANOLOL ESTER DERIVATIVE IN RAT SMALL INTESTINE Drug Metab. Dispos., March 1, 2006; 34(3): 398 - 404. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Okudaira, I. Komiya, and Y. Sugiyama Polarized Efflux of Mono- and Diacid Metabolites of ME3229, an Ester-Type Prodrug of a Glycoprotein IIb/IIIa Receptor Antagonist, in Rat Small Intestine J. Pharmacol. Exp. Ther., November 1, 2000; 295(2): 717 - 723. [Abstract] [Full Text] |
||||
![]() |
N. Okudaira, T. Tatebayashi, G. C. Speirs, I. Komiya, and Y. Sugiyama A Study of the Intestinal Absorption of an Ester-Type Prodrug, ME3229, in Rats: Active Efflux Transport as a Cause of Poor Bioavailability of the Active Drug J. Pharmacol. Exp. Ther., August 1, 2000; 294(2): 580 - 587. [Abstract] [Full Text] |
||||